Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.

Ramakrishnan V, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, O'Hara C, Powers DB, Liu G, Grove J, Hevezi P, Cass KM, Watson S, Evangelista F, Powers RA, Finck B, Wills M, Caras I, Fang Y, McDonald D, Johnson D, Murray R, Jeffry U.

J Exp Ther Oncol. 2006;5(4):273-86.

PMID:
17024968
2.

A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.

Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V.

J Transl Med. 2007 Nov 27;5:61.

3.

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients.

Ng CM, Bai S, Takimoto CH, Tang MT, Tolcher AW.

Cancer Chemother Pharmacol. 2010 Jan;65(2):207-17. doi: 10.1007/s00280-009-1023-8.

PMID:
19468731
4.

Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.

Bhaskar V, Fox M, Breinberg D, Wong MH, Wales PE, Rhodes S, DuBridge RB, Ramakrishnan V.

Invest New Drugs. 2008 Feb;26(1):7-12. Epub 2007 Sep 1.

PMID:
17786386
5.
6.
7.

Joint Antiangiogenic Effect of ATN-161 and Anti-VEGF Antibody in a Rat Model of Early Wet Age-Related Macular Degeneration.

Wang WQ, Wang FH, Qin WX, Liu HY, Lu B, Chung C, Zhu J, Gu Q, Shi W, Wen C, Wu F, Zhang K, Sun XD.

Mol Pharm. 2016 Sep 6;13(9):2881-90. doi: 10.1021/acs.molpharmaceut.6b00056. Epub 2016 May 9.

PMID:
27089240
8.

Combination therapy for age-related macular degeneration.

Patel S.

Retina. 2009 Jun;29(6 Suppl):S45-8. doi: 10.1097/IAE.0b013e3181ad22d5.

PMID:
19553801
9.

Volociximab in cancer.

Almokadem S, Belani CP.

Expert Opin Biol Ther. 2012 Feb;12(2):251-7. doi: 10.1517/14712598.2012.646985. Epub 2011 Dec 22. Review.

PMID:
22192080
10.

A novel integrin alpha5beta1 antagonistic peptide, A5-1, screened by Protein Chip system as a potent angiogenesis inhibitor.

Kim EY, Bang JY, Chang SI, Kang IC.

Biochem Biophys Res Commun. 2008 Dec 26;377(4):1288-93. doi: 10.1016/j.bbrc.2008.10.166. Epub 2008 Nov 7.

PMID:
18996355
11.

Anti-angiogenic function of tocotrienol.

Miyazawa T, Shibata A, Nakagawa K, Tsuzuki T.

Asia Pac J Clin Nutr. 2008;17 Suppl 1:253-6.

12.

Single and combined effects of alphavbeta3- and alpha5beta1-integrins on capillary tube formation in a human fibrinous matrix.

Laurens N, Engelse MA, Jungerius C, Löwik CW, van Hinsbergh VW, Koolwijk P.

Angiogenesis. 2009;12(3):275-85. doi: 10.1007/s10456-009-9150-8. Epub 2009 May 16.

13.

Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.

Pernasetti F, Nickel J, Clark D, Baeuerle PA, Van Epps D, Freimark B.

Int J Oncol. 2006 Dec;29(6):1371-9.

PMID:
17088974
14.

Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.

Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY, Davis PJ.

Angiogenesis. 2008;11(2):183-90. Epub 2007 Dec 13.

PMID:
18080776
15.
16.

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.

Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M, Hellström M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Ylä-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K.

Nature. 2008 Jul 31;454(7204):656-60. doi: 10.1038/nature07083. Epub 2008 Jun 25.

PMID:
18594512
17.

A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha5beta1 integrin.

Soro S, Orecchia A, Morbidelli L, Lacal PM, Morea V, Ballmer-Hofer K, Ruffini F, Ziche M, D'Atri S, Zambruno G, Tramontano A, Failla CM.

Blood. 2008 Apr 1;111(7):3479-88. doi: 10.1182/blood-2007-03-077537. Epub 2008 Jan 9.

18.

Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.

Shibata A, Nakagawa K, Sookwong P, Tsuzuki T, Oikawa S, Miyazawa T.

Biochem Pharmacol. 2008 Aug 1;76(3):330-9. doi: 10.1016/j.bcp.2008.05.017. Epub 2008 May 28.

PMID:
18599020
19.

CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling.

Léveillé C, Bouillon M, Guo W, Bolduc J, Sharif-Askari E, El-Fakhry Y, Reyes-Moreno C, Lapointe R, Merhi Y, Wilkins JA, Mourad W.

J Biol Chem. 2007 Feb 23;282(8):5143-51. Epub 2006 Dec 19.

20.

Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo.

Xiao D, Singh SV.

Cancer Res. 2007 Mar 1;67(5):2239-46.

Supplemental Content

Support Center